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Growing attention has been focussed towards a considerable amount of experimental and theoretical study of anti 
toxoplasmosis compounds having inhibitory activities against toxoplasmosis. Toxoplasmosis is a dangerous disease in both 
urban as well as rural areas. It is caused by Toxoplasma gondii. The life cycle involves feline species such as both domestic 
and wild cats, and other felids such as lions, etc. There are various targets for developing anti toxoplasmosis agents. One of 
the most promising targets is dihydrofolate reductase (DHFR). 1,3,5-Triazine compounds have been reported to inhibit the 
T. gondii. But there is hardly any formulation of quantitative structure-activity relationship (QSAR) involving 1,3,5-triazine
inhibitors to date. Therefore, it is our target in the present study to develop QSAR models based on the computed theoretical
molecular descriptors to scale the essential features responsible for the DHFR inhibition. These screened features of the
selected compounds will help to design the potent congeneric series.
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Toxoplasmosis is a major zoonotic parasitic disease 
that transmits from animals to human beings. In the 
life cycle of the disease, warm-blooded animals like 
feline cat and intermediate host human beings are 
involved. The infection is transmitted through the 
eating of infected meat and vegetables and also by 
drinking infected water, unpasteurized milk, and 
blood transfusion
1
. The microorganism responsible 
for the toxoplasmosis is Toxoplasma gondii which 
approximately infects a third of the world’s population 
i.e. one-third population is serum positive. This is the
most dangerous parasite
2
. The deadly impact of
infection during pregnancy and its reactivation in
immune-compromised patients are well known for a
long time although progress has been made in the
field of its diagnosis, epidemiology, and understanding
of the relationship between parasite and cell
3
. In expectant
women and patients with a compromised immune
system, T. gondii causes grave damage and fetus loss.
The graveness of infection is dependent on the
gestation stage. The first trimester and the last




The introduction of antiretroviral therapy in 
high-income countries cause the reduction of HIV-
associated Toxoplasma but still not in low-income 
countries
5
. The therapy targets a different T. gondii 
enzymes such as farnesyl diphosphate/geranylgeranyl- 
diphosphate, bumped kinase, fatty acid synthase II 
(FAS II), histone acetyltransferase/histone deacetylase, 
and dihydrofolate reductase (DHFR). Dihydrofolate is 
converted to tetrahydrofolate by the DHFR enzyme 
which is present in living organisms such as bacteria, 
plants, and mammals. Inhibition of DHFR enzyme 
causes disturbance in the synthesis of protein, RNA, 
DNA because the level of THF becomes lower which 
is responsible for the synthesis. So, the disease caused 
by these pathogens can weaken our immune system 
and DHFR inhibition is the most important and 
effective treatment for it
6
. 
Pyrimethamine along with sulfadiazine which targets 
DHFR is the first-line treatment for toxoplasmosis. 
Pyrimethamine is a folic acid antagonist and can cause 
dose-related suppression of the bone marrow, which 
is mitigated by concurrent administration of folinic 
acid (leucovorin). Leucovorin is added to the above 
combination to prevent hematologic toxicity. 
Pyrimethamine-sulfadiazine was later discontinued 
owing to toxicity and severe side effects in 62% and 
44% of patients respectively. The condition of 
the above trials were toxoplasma encephalitis. 
Clindamycin was an able substitute for sulfadiazine for 




patients susceptible to sulfa drugs. Clindamycin 
however couldn’t prevent relapse and the same level of 
toxicity. In patients resistant to sulfa susceptibility 
sulfadiazine was replaced with sulfamethoxazole. For 
patients who couldn’t tolerate pyrimethamine or due to 
its unavailability, it was replaced with trimethoprim. 
Azithromycin and atovaquone can be used in place of 
sulfadiazines or pyrimethamine in the event of 
contraindications. The combination of pyrimethamine 
and sulfadiazine is also known to cause serious side 
effects such as Stevens-Johnson syndrome, liver 
necrosis, toxic necrosis, etc. It is widely known that 
congenital infection, ocular infection, and accidental 
infection require a prolonged treatment regime of 4-6 
weeks to at least one year to kill the cysts formed in 
tissue. Atovaquone is a promising candidate and is 
known to act against tissue cysts in T. gondii. At the 
same time, atovaquone has failed to prevent relapse in 
the cases of ocular infection and encephalitis
7-11
. 
Therefore it requires the development of new drugs with 
reduced toxicity and improved efficacy towards the 
prevention of infection. As DHFR is a potential target of 
T. gondii, it has been tried to design and discover new 
DHFR inhibitors. The potent class of drugs acting 
against DHFR is dihydrotriazines. The dihydrotriazines 
have been effective against both malaria and T. gondii. 
But there are hardly any studies reported on the  
design of this class of congeners using quantitative 
structure-activity relationships (QSAR). So it is our 
target in the present study to develop QSAR models 
using computed structural properties of these 
compounds. The modeled parameters can give a clue for 




Several 60 halogenated compounds based on 1,3,5-
triazine
12
 with varied potency toward T. gondii 
dihydrofolate reductase inhibition have been taken into 
consideration to form the activity dataset (Table I). 
Activity data is given in the following Table I. The 
structures of all compounds under study were drawn in 
the 2D ChemDraw window. The drawn structures were 
then imported into 3D modules using the default 
conversion procedure implemented in the CS Chem3D 
Ultra
13
. A further process is to minimize the energy of 
these compounds up to 0.01 by the MM2 molecular 
field. All the minimized ligands were browsed into 
PaDEL software
14
 to calculate many 1875 theoretical 
molecular descriptors including electrostatic, topological, 
constitutional, geometrical, and physicochemical, useful 
for our purpose, and before model development, these 
were reduced to 672. 
Descriptors with perfectly constant and highly 
inter-correlated descriptors were removed considering 
variance and correlation coefficient cut-off values  
of 0.0001 and 0.99 using the V-WSP algorithm
15
 
incorporated into the vWSP module of Nano 
BRIDGES software
16
. The reduced set of theoretical 
molecular descriptors was taken into consideration for 
the development of quantitative structure-activity 
relationship models. 
As the number of structural predictors greatly 
exceeds the number of compounds, the selection of 
important predictors is necessary for QSAR modeling. 
A genetic algorithm coupled with multiple linear 
regression methodology has been applied in the 
present work to screen the class of descriptors having 
a higher impact on the anti Toxoplasmosis activities 
of 1,3,5 triazine compounds. The quality of the model 
is calculated by the fitness function by taking 100 
different random combinations of the calculated 
molecular descriptors. The fitness function of each 







Loo represents cross-validated R
2










Result and Discussion 
The total data set consists of 60 halogenated 1,3,5-
triazine compounds. Several training and test set was 
randomly generated. Many training QSAR models 
have been developed utilizing various sets of 
computed molecular descriptors using GA-MLR 
methods of NanoBridges software. The best model is 
produced while the total data set was divided into 
training (75%) and test sets (25%) on a random basis. 
The best training QSAR model is given below. 
PIC50 = -3.177(+/-1.412) + 6.957(+/-0.921) E1v + 
3.662(+/-0.454) CIC2 + 0.853(+/-0.390) nHBint4 + 
0.053(+/-0.011) AATSC6m - 0.174(+/-0.032) 
nAtomP + 0.760(+/-0.254) SHdsCH  
N = 49, R
2
 = 0.791, QLoo
2
 = 0.659, Rpred
2
 = 0.548, 
PRESS = 17.928, SE=0.518            Eq. 1 







and SE represent the number of observations, squared 





, the predictive sum of 
square deviations, and standard error of the regression 
model, respectively.  
 
 

















S.No. R1 R2 R3 pIC50 
1* Cl H H 0.107 
2* Cl Cl H 2.657 
3 H H Cl −1.927 
4 H Cl H 0.657 
5 H Br H 1.187 
6 Cl H Cl −1.748 
7 F CF3 H 0.769 











S.No. R1 R2 − pIC50 
9 OCH3 H − 0.148 
10 SCH3 H − −0.181 
11 SCH2CH3 H − 0.602 
12 SO2CH2CH3 H − −0.949 
13 OCH2CH3 H − −0.491 
14* N(CH2CH2C1)2 H − 0.481 
15 NH2 H − −0.158 
16 CH2NH2 H − −0.919 
17* H SO2F − 0.468 













S.No. R1 R2 R3 X pIC50 
19 Cl H Cl (CH2)4 1.468 
20 SO2F H H CH2CH2CONH 1.522 
21* SO2F H H CH2CONH 0.721 
22 SO2F CH3 H CH2CH2CONH 1.283 
23 H SO2F H CONH −1.838 
24 H SO2F H CH2CH2CONH 1.173 
25 SO2F H H CH2CH2CONHSO2 0.823 
(Contd.) 




Table I — Biological activity data of 1,3,5-triazine compounds 
26 H SO2F H OCH2CONH 1.585 
27* NO2 H H OCH2CH2O 1.568 
28 NH2 H H OCH2CH2O 1.494 
29 NHCOCH2Br H H OCH2CH2O 1.958 
30 H H H (CH2)4 1.585 
31 H H H (CH2)2 1.920 
32 H CH3 H CH2CH2CONH 1.552 
33* H H H CH(CN)(CH2)3 1.508 













S.No. R1 R2 R3 X pIC50 
35* Cl H Cl (CH2)4 1.795 
36 H H H (CH2)4 1.638 
37 H NHCOCH2Br H OCH2 0.113 
38 NH2 H H O(CH2)3O 1.522 
39* NHCOCH2Br H H O(CH2)3O 1.251 
40 H NH2 H OCH2 0.568 
41 H NH2 H (CH2)4 1.823 
42 H NO2 H OCH2 0.853 
43 H NO2 H (CH=CH)2 1.000 
44 H NO2 H O(CH2)2O 1.397 
45 H NHCOCH2Br H O(CH2)2O 0.721 
46 H NHCOCH2Br H O(CH2)3O 0.346 
47 H NO2 H O(CH2)3O 1.481 
48 NH2 H H O(CH2)2O 1.958 
49 NHCOCH=CHCOOH H H O(CH2)2O 2.292 
50 NHCOCH=CHCOOH H H O(CH2)3O 2.376 
51* NO2 H H O(CH2)2O 1.619 
52 NO2 H H O(CH2)3O 1.522 
53 SO2F H H CH2CONH 0.853 
54 SO2F H H (CH2)2CONH 0.920 
55* SO2F H H CONH −1.463 
56 H H H (CH2)2 2.000 
57 H H H (CH2)4O 2.337 
58 SO2F Cl H (CH2)4 1.408 
59 H H H CH2CONH 1.075 
60 H CON(CH3)2 H CH2NHCONH 0.966 
* Test set 
 
To validate the further predictive power of the 
models, QSAR model Eq. 1 is used to predict the 
biological activities of the corresponding test set 
compounds which are taken as 1, 2, 14, 17, 18, 21, 27, 
33, 35, 39, 51, and 55 which were shown by an 
asterisk in Table I. The square correlation between 
observed and predicted activities has been calculated 
as 0.596 which stands as significant model validation 
(Figure 1). The modeled parameters are described in 
Table II. 





The above QSAR studies predicted the crucial 
features such as E1v, CIC2, AATSC6m, nHBint4, and 
many =CH- group of the studied 1,3,5-triazine 
compounds are responsible for producing the 
inhibition of T. gondii DHFR. The groups having 
large van der Waals volume and greater molecular 
size encoding descriptors of E1v and CIC2 having a 
positive coefficient may give a positive contribution 
towards T. gondii DHFR inhibition. The descriptor 
AATSC6m indicates average centered Broto-Morau 
autocorrelation-lag 6/weight by mass and is favorable 
for the enzyme inhibition. The nHBint4 representing 
potential hydrogen bonding is favorable for DHFR 
inhibition. An increase in the sum of atom-type 
hydrogen E-State for a group of =CH- may inhibit  
T. gondii DHFR. It may impart nonpolar 
hydrophobicity. The decrease in molecular property 
such as nAtomP representing Pi-stacking interactions 
may increase the biological activity. 
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Figure 1 — Observed vs. predicted activity of test set compound (Eq. 1) 
 
Table II — Physical interpretation of the modeled parameters 
Name of the descriptors Interpretation 
E1v 1st component accessibility directional WHIM index / weighted by van der Waals volume 
CIC2 Complementary Information Content index (neighborhood symmetry of 2-order) 
nHBint4 Count of E-State descriptors of strength for potential hydrogen Bonds of path length 4 
AATSC6m Average centered Broto-Morau autocorrelation-lag 6/weight by mass 
nAtomP Number of atoms in the largest pi system 
SHdsCH Sum of atom-type hydrogen E-State: =CH- 
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